

**Remarks**


Claims 1-26 are pending in the instant application. Applicants have amended claims 1-21 and 25-26 to more fully conform with U.S. practice and cancelled claim 24, without prejudice.

The enclosed substitute specification in compliance with 37 CFR 1.121(b)(3) and 1.125 is for publication purposes and does not contain any markings. It includes a new first paragraph cross referencing the related priority applications.

Applicants also provide herewith a copy of the published international application, international search report, international preliminary report on patentability, written opinion and search report from the Patent Office of Great Britain, which issued on the priority application. Enclosed is Form PTO-1449 listing the references along with a copy of the non-US patent publications cited thereon.

Applicants respectfully assert that all amendments are fairly based on the specification, and respectfully request their entry. Applicants believe that the claims, as amended, are in allowable form and earnestly solicited the allowance of claims 1-23 and 25-26.

Respectfully submitted,

  
Yonggang Ji  
Registration No.: 53,073  
Agent for Applicants

**Customer No.: 22840**

Amersham Biosciences Corp  
Patent Department  
800 Centennial Avenue  
Piscataway, New Jersey 08855-1327

Tel: (732) 980-2875  
Fax: (732) 457-8463